ReviewTrends in cancer2018
Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment.
Review in Trends in cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 166 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
166 citing papers in PubMed, 2 syntheses or guidelines pooled it, 292 citations in OpenAlex.
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Pooled it
- cDC2 and plasmacytoid dendritic cells diminish from tissues of patients with non-Hodgkin orbital lymphoma and idiopathic orbital inflammation.European journal of immunology · 2020Pooled it
- Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial.Frontiers in immunology · 2019Trial
- Antigen presentation requirements for effective cDC1-based cancer immunotherapy.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- The Central Role of HLA Class II-Restricted Helper Neoantigen Vaccines in Cancer Immunotherapy.Cancers · 2026Review
- Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics.Signal transduction and targeted therapy · 2026Review
- A plant vesicle-dendritic cell chimera for enhancing cancer immunotherapy.Nature communications · 2026Article
- Nanotechnology-Based Cancer Vaccines: Translational Barriers and Emerging Strategies.Vaccines · 2026Review
- Preclinical efficacy of dendritic cells loaded with newly identified HPV11 E6-derived CD8NPJ vaccines · 2026Article
- From conceptual design to translational progress: Emerging advances in intelligent microneedles for biomedical applications.Acta pharmaceutica Sinica. B · 2026Review
- MicroRNA-mediated modulation of cancer-associated fibroblasts in HER2-positive breast tumor microenvironment: a comprehensive review.Discover oncology · 2026Review
- Antigen presentation requirements for effective cDC1-based cancer immunotherapy.bioRxiv : the preprint server for biology · 2026Article
- Soluble multi-epitope protein vaccination leverages antigen availability to drive CD8Frontiers in immunology · 2026Article
- Case Report: Primed dendritic cell immunotherapy for multiple solid tumors.Frontiers in immunology · 2026Article
- Harnessing the abscopal effect: mechanistic insights and therapeutic strategies for systemic cancer immunotherapy.Frontiers in immunology · 2026Review
- The Multifaceted Role of Annexin A1 in Colorectal Cancer: From Molecular Mechanisms to Predictive and Prognostic Implications.Medical sciences (Basel, Switzerland) · 2025Review
- GPC3-based circular RNA vaccine suppresses hepatocellular carcinoma progression by activating adaptive immune responses.Hepatology (Baltimore, Md.) · 2025Article
- CD8+ T Cells Primed by Antigenic Peptide-Pulsed B Cells or Dendritic Cells Generate Similar Anti-Tumor Response.Vaccines · 2025Article
- Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025Review
- Eliciting antitumor immunity via therapeutic cancer vaccines.Cellular & molecular immunology · 2025Review
106 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Dendritic cells (DCs) are essential in immunity owing to their role in activating T cells, thereby promoting antitumor responses. Tumor cells, however, hijack the immune system, causing T cell exhaustion and DC dysfunction. Tumor-induced T cell exhaustion may be reversed through immune checkpoint blockade (ICB); however, this treatment fails to show clinical benefit in many patients. While ICB serves to reverse T cell exhaustion, DCs are still necessary to prime, activate, and direct the T cells to target tumor cells. In this review we provide a brief overview of DC function, describe mechanisms by which DC functions are disrupted by the tumor microenvironment, and highlight recent developments in DC cancer vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.